STAT

OCTOBER 11, 2023

Chronic kidney disease was the strongest risk factor for sudden cardiac arrest among Hispanic and Latino adults in the first study to evaluate this population in the U.S. for risk factors of this major cause of death. Read the rest…

Hospitals 118

Hospitals 118

Hospital Pharmacy Europe

JANUARY 17, 2024

The National Institute for Health and Care Excellence (NICE) has recommended that empagliflozin can be used as an option for treating chronic kidney disease (CKD) in adults under some circumstances. Empagliflozin was approved by the European Medicines Agency for the treatment of adult patients with CKD in July 2023.

Hospitals 105

Hospitals 105

STAT

MAY 22, 2023

In 2012, the United States Preventive Services Task Force convened to determine whether it should recommend kidney disease screening for all Americans. Advocates had been pushing for it, citing ballooning rates of chronic kidney disease. That paradigm has since shifted, says Marika Cusick, a Ph.D.

106

106

European Pharmaceutical Review

JULY 26, 2023

The European Commission (EC) has approved Jardiance ® (empagliflozin) for adults with chronic kidney disease (CKD). We celebrate this significant milestone [for this new treatment option] in the field of chronic kidney disease,” commented Daniel Gallego, President of European Kidney Patients’ Federation.

Labelling 95

Labelling Hospitals 95

Pharmafile

NOVEMBER 6, 2023

AstraZeneca has announced results from the ZENITH-CKD phase 2b clinical trial for the combination of zibotentan with dapagliflozin for the treatment of patients with chronic kidney disease (CKD) and proteinuria.

64

64

Drug Store News

APRIL 7, 2023

DSN interviewed Omar Abdelsamad, executive director of patient recruitment, clinical trial services at CVS Health, about the company’s entry into a new therapeutic space—chronic kidney disease.

98

98

Pharmaceutical Technology

MAY 17, 2023

Chinook Therapeutics and Ionis Pharmaceuticals have entered a partnership to develop an antisense oligonucleotide (ASO) therapy to treat a rare, severe chronic kidney disease. Antisense therapies are designed for destroying mRNA, reducing the amount of disease-causing protein.

98

98

European Pharmaceutical Review

OCTOBER 18, 2023

Ardelyx’s first-in-class oral treatment is indicated to reduce serum phosphorus in adults with chronic kidney disease ( CKD ) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant to phosphate binder therapy.

FDA 114

FDA Adverse Reactions Labelling 114

STAT

SEPTEMBER 19, 2022

Chronic kidney disease, already a problem affecting millions of Americans , is only expected to become more prevalent as the country ages. For those with the disease, a transplant is the ideal treatment, but dialysis is their reality. As an industry, dialysis has significant flaws, including a lag in home dialysis use.

100

100

Hospital Pharmacy Europe

JULY 27, 2023

Empagliflozin has become the first SGLT2 inhibitor to be approved by the European Medicines Agency (EMA) for the treatment of adult patients with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company have announced. Hence, any treatment that slows disease progression offers a clinical benefit to patients.

Hospitals 52

Hospitals 52

European Pharmaceutical Review

NOVEMBER 7, 2022

Results from the EMPA-KIDNEY Phase III clinical trial announced at the American Society of Nephrology (ASN)’s Kidney Week 2022, demonstrated Jardiance ® (empagliflozin) reduced the risk of kidney disease progression or cardiovascular death by 28 percent versus placebo in adults with chronic kidney disease (CKD).

86

86

The Checkup by Singlecare

JANUARY 10, 2024

Pain under the right rib cage, also known as the right upper quadrant (RUQ) of the ribs, could be due to a variety of conditions, considering this is where the pancreas, right kidney, gallbladder, liver, and part of the intestines are located. Read more about treatments for kidney stones , preeclampsia , and asthma.

Mayo Clinic 98

Mayo Clinic 98

The Checkup by Singlecare

APRIL 18, 2024

Jardiance is a medication mainly used to manage blood sugar levels in adults with Type 2 diabetes, but it may also help reduce the risk of complications in people with chronic kidney disease (CKD). Its active ingredient, empagliflozin, works by blocking a process that reabsorbs blood sugar from the kidneys back into the body.

Dosage 52

Dosage Hospitals FDA 52

The Checkup by Singlecare

DECEMBER 12, 2023

While deficiency of any of the water-soluble vitamins can result in a serious clinical syndrome, deficiency of water-soluble vitamins is rare in the United States. Vitamin A overdose can present as either an acute toxicity or a chronic toxicity. Later in chronic toxicity, severe headaches and generalized weakness may develop.

Mayo Clinic 124

Mayo Clinic Compounding Immunization 124

Hospital Pharmacy Europe

AUGUST 24, 2023

An oral, delayed-release budesonide formulation provides a clinically relevant reduction in estimated glomerular filtration rate (eGFR) decline and a durable reduction in proteinuria versus placebo in patients with primary IgA nephropathy (IgAN), a new study has shown. For example, after the two-year period, there was a 6.11 mL/min/1.73

Immunization 91

Immunization FDA Hospitals 91

STAT

JUNE 11, 2023

billion upfront, picking up two drugs for a chronic kidney disease that are in late-stage clinical trials.   LONDON — Novartis said on Monday it would purchase Chinook Therapeutics for $3.2 The agreement includes another $300 million if certain regulatory milestones are reached.

97

97

pharmaphorum

FEBRUARY 21, 2022

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies from AstraZeneca and Johnson & Johnson.

FDA 121

FDA 121

Pharmaceutical Technology

JANUARY 10, 2023

CinCor Pharma is focused on developing new treatments for chronic kidney disease and resistant and uncontrolled hypertension. It is currently in clinical development to treat hypertension and primary aldosteronism. AstraZeneca stated that the transaction would boost its cardiorenal pipeline by adding baxdrostat.

97

97

STAT

DECEMBER 6, 2023

This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong. Medicare spending on people with advanced metabolic disease is sobering. Yet beneath the hype lies a real fear. That will be costly.

Insurance 114

Insurance 114

European Pharmaceutical Review

OCTOBER 16, 2023

billion, Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences. To date, the small molecule drug has been evaluated in nine clinical trials. In a deal of up to $1.3

59

59

Pharmaceutical Technology

OCTOBER 27, 2023

DF-003 is under clinical development by Drug Farm and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure).

52

52

Pharmaceutical Technology

OCTOBER 27, 2023

DF-003 is under clinical development by Drug Farm and currently in Phase I for Chronic Kidney Disease (Chronic Renal Failure).

52

52

PharmD Live

JUNE 13, 2022

Because of the insidious nature of chronic kidney disease, and because most people affected do not have symptoms until the condition becomes advanced, it is sometimes under-recognized by busy healthcare providers. Of these 37 million Americans, approximately 90% of them with chronic kidney disease don’t know they have it.

Hospitals 52

Hospitals 52

Pharmafile

JANUARY 9, 2023

AstraZeneca has announced that it is set to acquire the clinical-stage biopharmaceutical company CinCor in a deal worth up to $1.8bn. US-based CinCor focuses on the development of novel treatments for resistant and uncontrolled hypertension, as well as to treat chronic kidney disease. read more.

78

78

pharmaphorum

MARCH 3, 2022

The results of the EMPULSE trial showed that adults hospitalised for acute heart failure were 36% more likely to see an improvement on clinical measures – including all-cause mortality, frequency of heart failure events, time to first heart failure event, and symptoms – in the first 90 days after treatment started compared to placebo.

Labelling 98

Labelling Hospitals 98

The People's Pharmacy

MAY 18, 2023

The CDC estimates that some chronic condition afflicts as many as one in six American adults. Add heart disease and cancer, and you have covered a large number of people. Add heart disease and cancer, and you have covered a large number of people. Arthritis, chronic kidney disease, emphysema and diabetes affect even more.

91

91

Hospital Pharmacy Europe

AUGUST 24, 2023

An oral and targeted release budesonide formulation provided a clinically relevant reduction in eGFR decline and a durable reduction in proteinuria versus placebo, in patients with IgA nephropathy. IgA nephropathy is a chronic immune-mediated kidney disease characterised by IgA deposition in the glomeruli. mL/min/1.73

Immunization 52

Immunization FDA Hospitals 52

European Pharmaceutical Review

JANUARY 9, 2023

The deal also offers the possibility for baxdrostat (CIN-107) to be combined with Farxiga ( dapagliflozin ), helping to address cardiorenal diseases, where there is a high unmet medical need. In clinical trials, baxdrostat was observed to significantly lower aldosterone levels without affecting cortisol levels, across a wide range of doses.

92

92

Pharmaceutical Technology

MAY 23, 2023

The UK’s medicines and healthcare products regulatory agency (MHRA) has granted marketing authorisation for Akebia Therapeutics’ Vafseo (vadadustat) to treat symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients on chronic maintenance dialysis.

Labelling 52

Labelling 52

European Pharmaceutical Review

MAY 8, 2023

A marketing authorisation for PRX-102 (pegunigalsidase alfa) , the first Poly(ethylene glycol) (PEG)ylated enzyme for Fabry disease, has been granted by the European Commission (EC). CHMP recommends first pegylated enzyme for Fabry disease… The PEGylated enzyme replacement therapy Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc.

86

86

The Checkup by Singlecare

NOVEMBER 13, 2023

Causes of sharp right-side chest pain Sharp pain on the right side of the chest is a common clinical symptom, and it can be due to a variety of causes that may be related to the lungs, chest muscles, digestive system, or an infection. According to the Centers for Disease Control and Prevention (CDC) , about 16 million Americans have COPD.

Mayo Clinic 52

Mayo Clinic Vaccines Chemotherapy Communication 52

Pharmaceutical Technology

OCTOBER 27, 2022

Bayer has received approval from Health Canada for finerenone as an adjunct to standard-of-care treatment for chronic kidney disease (CKD) and type 2 diabetes (T2D) in adult patients. Health Canada approval is based on the positive data from the Phase III FIDELIO-DKD and FIGARO-DKD clinical trials of Kerendia.

Hospitals 52

Hospitals 52

The Checkup by Singlecare

JANUARY 26, 2024

Lower abdominal pain on the left side can be caused by an injury, inflammation, or infection of one of the following organs : Colon Small intestine Ovaries Uterus Ureters Bladder Peritoneum The kidneys are located closer to the back of the torso, but their proximity to the abdomen means kidney issues can also cause lower abdominal pain.

Mayo Clinic 52

Mayo Clinic Immunization Hospitals 52

European Pharmaceutical Review

JUNE 13, 2023

Chinook Therapeutics has two late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease. Clinical data has shown atrasentan has demonstrated significant reductions in proteinuria. IgA nephropathy IgAN is a progressive, rare kidney disease. The post £2.5b

Immunization 52

Immunization 52

The Checkup by Singlecare

MARCH 9, 2024

Unlike Ozempic, Jardiance works by preventing the kidneys from reabsorbing glucose, allowing it to be cleared from the body in urine. By managing blood sugar levels, these medications may help reduce the risks and complications associated with diabetes , such as heart disease, kidney disease, vision problems, and nerve damage.

Dosage 94

Dosage Insurance Insurance Coverage Labelling 94

European Pharmaceutical Review

FEBRUARY 7, 2023

The first-in-class, oral, once-daily SGLT2 inhibitor has shown efficacy in preventing and delaying cardiorenal disease, while also protecting the organs, research has shown. This was the largest clinical trial to date in HF patients with LVEF above 40 percent, with 6,263 randomised patients.

89

89

The Checkup by Singlecare

DECEMBER 29, 2023

Some healthcare providers recommend or prescribe creatine supplements to vegetarians who don’t get enough naturally occurring creatine in their diet and people with creatine deficiency disorders or diseases that reduce lean muscle mass. However, there are anecdotal reports of creatine side effects. Does creatine make you gain weight?

Dosage 94

Dosage Labelling FDA 94